Malaria Information and Prophylaxis, by Country [P]

The information presented in this table is consistent 1 with the information in the CDC Health Information for International Travel (the “Yellow Book”).

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Malaria Information and Prophylaxis by Country
Country Areas with Malaria Drug Resistance2 Malaria Species3 Recommended Chemoprophylaxis4 Key Information Needed and Helpful Links to Assess Need for Prophylaxis for Select Countries
Pakistan All areas (including all cities) at altitudes < 2,500 m (8,202 ft) Chloroquine P. vivax 70%,

P. falciparum 30%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Palau None Not Applicable Not Applicable Not Applicable
Panama Present in the provinces of Darien, Kuna Yala (also spelled Guna Yala), Ngäbe-Buglé, and eastern Panama province. None in Panama Oeste, the Canal Zone, and Panama City. Chloroquine (east of the Panama Canal) P. vivax 99%,

P. falciparum 1%

Provinces of Darien, Guna Yala, and eastern Panama province: Atovaquone-proguanil, doxycycline, mefloquine, primaquine, or tafenoquine6. Ngäbe-Buglé: Atovaquone-proguanil, chloroquine, doxycycline, mefloquine, primaquine,6 or tafenoquine.6
Papua New Guinea Present throughout country at altitudes < 2,000 m (6,562 ft) Chloroquine (both P. falciparum and P. vivax) P. falciparum 65-80%,

P. vivax 10-30%,

P. malariae and P. ovale rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Paraguay None Not applicable Not applicable Not applicable
Peru All departments < 2,000 m (6,561 ft), including the cities of Iquitos and Puerto Maldonado, and only the remote eastern regions of La Libertad and Lambayeque. None in the following areas: Lima Province; the cities of Arequipa, Ica, Moquegua, Nazca, Puno, and Tacna; the highland tourist areas (Cuzco, Machu Picchu, and Lake Titicaca); and along the Pacific Coast. Chloroquine P. vivax 85%,

P. falciparum 15%

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Philippines Present in Palawan and Mindanao Islands. None in metropolitan Manila and other urban areas. Chloroquine P. falciparum 70-80%,

P. vivax 20-30%,

P. knowlesi rare

Atovaquone-proguanil, doxycycline, mefloquine, or tafenoquine6
Pitcairn Islands (U.K.) None Not Applicable Not Applicable Not Applicable
Poland None Not Applicable Not Applicable Not Applicable
Portugal None Not Applicable Not Applicable Not Applicable
Puerto Rico (U.S.) None Not Applicable Not Applicable Not Applicable

1. Factors that affect local malaria transmission patterns can change rapidly and from year to year, such as local weather conditions, mosquito vector density, and prevalence of infection. Information in these tables is updated regularly.
2. Refers to P. falciparum malaria unless otherwise noted.
3. Estimates of malaria species are based on best available data from multiple sources.
4. Several medications are available for chemoprophylaxis. When deciding which drug to use, consider specific itinerary, length of trip, cost of drug, previous adverse reactions to antimalarials, drug allergies, and current medical history. All travelers should seek medical attention in the event of fever during or after return from travel to areas with malaria.
5. This risk estimate is based largely on cases occurring in US military personnel who travel for extended periods of time with unique itineraries that likely do not reflect the risk for the average US traveler.
6. Primaquine and tafenoquine can cause hemolytic anemia in persons with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Patients must be screened for G6PD deficiency prior to starting primaquine.

Page last reviewed: March 27, 2019